Sort   by:  
 Page size 
UnknownMeta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations.
Not available
S-EPMC5548880 | biostudies-literature
UnknownHSV ICP0 recruits USP7 to modulate TLR-mediated innate response.
Not available
S-EPMC3401030 | biostudies-literature
UnknownOncogenic properties of wild-type DNA repair gene FANCA in breast cancer.
Not available
S-EPMC12139098 | biostudies-literature
UnknownPrevalence, clinical characteristics and prognosis of EBV-positive follicular lymphoma.
Not available
S-EPMC6374505 | biostudies-literature
UnknownA systematic literature review and meta-analysis on the efficacy and safety of PD-(L)1 inhibitors for the first- and second-line treatment of locally advanced or metastatic non-small cell lung cancer in Asian and non-Asian patients.
Not available
S-EPMC12775713 | biostudies-literature
UnknownSingle-Cell RNA Profiling of Ocular Adnexal Sebaceous Carcinoma Reveals a Complex Tumor Microenvironment and Identifies New Biomarkers.
Not available
S-EPMC11735305 | biostudies-literature
UnknownGenomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens.
Not available
S-EPMC12065606 | biostudies-literature
UnknownComparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
Not available
S-EPMC9527668 | biostudies-literature
UnknownColesevelam for Lenalidomide Associated Diarrhea in Patients with Multiple Myeloma.
Not available
S-EPMC11177961 | biostudies-literature
UnknownReal-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Not available
S-EPMC10432623 | biostudies-literature
Sort   by:  
 Page size